Nevro Corp., a global medical device company, today announced that its Senza system has been successfully approved by the FDA for the treatment of chronic pain associated with painful diabetic neuropathy (PDN). With the approval, the company will immediately begin its commercial production in the United States.
NeuroSigma, Inc., a bioelectronic medical device company, today announced that the company received an equity investment of USD 5 million from KT Corporation, an international digital telecommunication company. With the investment, the company will support the commercialization and development of Monarch eTNS Systems and accelerate the business growth trajectory of NeuroSigma.
Author Credits: Radhika Gupta, Shivam Bhutani